Shaanxi Meibang Pharmaceutical Group Past Earnings Performance
Past criteria checks 1/6
Shaanxi Meibang Pharmaceutical Group has been growing earnings at an average annual rate of 10.2%, while the Chemicals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 10.7% per year. Shaanxi Meibang Pharmaceutical Group's return on equity is 5.2%, and it has net margins of 8.2%.
Key information
10.2%
Earnings growth rate
2.7%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 10.7% |
| Return on equity | 5.2% |
| Net Margin | 8.2% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shaanxi Meibang Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 699 | 58 | 119 | 59 |
| 30 Sep 23 | 776 | 104 | 121 | 61 |
| 30 Jun 23 | 765 | 102 | 129 | 71 |
| 31 Mar 23 | 763 | 123 | 122 | 74 |
| 31 Dec 22 | 906 | 145 | 159 | 80 |
| 30 Sep 22 | 976 | 174 | 165 | 76 |
| 30 Jun 22 | 984 | 173 | 161 | 73 |
| 31 Mar 22 | 1,055 | 171 | 168 | 76 |
| 31 Dec 21 | 842 | 126 | 120 | 64 |
| 30 Sep 21 | 706 | 91 | 92 | 55 |
| 30 Jun 21 | 679 | 84 | 82 | 58 |
| 31 Mar 21 | 625 | 82 | 72 | 54 |
| 31 Dec 20 | 569 | 79 | 62 | 51 |
| 31 Dec 19 | 516 | 76 | 60 | 40 |
| 31 Dec 18 | 439 | 59 | 54 | 27 |
| 31 Dec 17 | 422 | 61 | 48 | 26 |
Quality Earnings: 605033 has a large one-off loss of CN¥18.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 605033's current net profit margins (8.2%) are lower than last year (16%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605033's earnings have grown by 10.2% per year over the past 5 years.
Accelerating Growth: 605033's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 605033 had negative earnings growth (-60.3%) over the past year, making it difficult to compare to the Chemicals industry average (-24.7%).
Return on Equity
High ROE: 605033's Return on Equity (5.2%) is considered low.